Navigation Links
Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
Date:9/18/2007

F="http://www.millennium.com" target="_new">http://www.millennium.com . Following the webcast, an archived version of the call will be available at the same address for 30 days.

About Multiple Myeloma

Multiple myeloma is the second most common hematologic malignancy and although the disease is predominantly a cancer of the elderly (the average age of onset is 65 to 70 years of age), recent statistics indicate both increasing incidence and younger age of onset. In the U.S., more than 50,000 individuals have MM and 20,000 new cases are diagnosed each year. Worldwide there are approximately 74,000 new cases and over 45,000 deaths annually.

About VELCADE

VELCADE is being co-developed by Millennium Pharmaceuticals, Inc. and JJPRD. Millennium is responsible for commercialization of VELCADE in the U.S., Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. For a limited period of time, Millennium and Ortho Biotech Inc. are co-promoting VELCADE in the U.S. VELCADE is approved in more than 80 countries worldwide.

In the U.S., VELCADE is indicated for the treatment of patients with multiple myeloma who have received at least one prior therapy. VELCADE is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy. In the European Union and many other countries worldwide, VELCADE is approved for patients with multiple myeloma after first relapse.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and t
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... JOLLA, Calif., Aug. 4, 2015   Regulus ... biopharmaceutical company leading the discovery and development of ... and highlights for the quarter ended June 30, ... highlights.  "The second quarter of ... of progression for Regulus," said Paul Grint, M.D., ...
(Date:8/4/2015)... , Aug. 4, 2015 Levi & Korsinsky ... ("Biogen" or the "Company") (NASDAQGS: BIIB) for possible violations ... and certain of its officers and/or directors have violated ... of 1934.  On Friday, July 24, 2015, prior to ... quarter 2015 financial results. Among other things, the Company ...
(Date:8/4/2015)... Aug. 4, 2015  Sutro Biopharma today announced ... Ph.D., as vice president of alliance and project ... in the management of Sutro,s collaborative partnerships and ... antibody-drug conjugates, bispecific antibodies and antibody-based therapeutics targeting ... than 22 years of experience in the biopharmaceutical ...
Breaking Medicine Technology:Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 2Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 3Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 4Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 5Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 6Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 7Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 8Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 9Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 10SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation of Biogen Inc. and Its Board of Directors in Connection with Possible Violations of Federal Securities Laws -- BIIB 2Sutro Biopharma Appoints Nicki Vasquez, Ph.D. as VP of Alliance and Project Management 2
... 2012 Ziehm Imaging, leading developer, ... award-winning product portfolio at this year,s Charing Cross ... ), its UK distribution partner, Ziehm Imaging showcases ... cardiologists to provide them with a flexible, cost-efficient ...
...  NxStage Medical, Inc. (Nasdaq: NXTM ), a ... to release its financial results for the first quarter ... before the opening of the financial markets. ... also host a conference call at 9:00 a.m. Eastern ...
Cached Medicine Technology:CX 2012: Elevating the Boundaries of Interventional Imaging with Mobile C-arms 2NxStage® to Report First Quarter Fiscal 2012 Financial Results 2
(Date:8/4/2015)... (PRWEB) , ... August 05, 2015 , ... The ... Pain and Obesity ”. , As corresponding author Professor Akiko Okifuji says “Both obesity ... often, although it is not to say that one causes the other. Rather, there ...
(Date:8/4/2015)... ... August 04, 2015 , ... assistPoint Partners, LLC is ... oncology patient assistance programs. Through a secure web portal, assistPoint connects Life Sciences, ... enterprise level, cloud-based application and workflow solution. This provides cancer center patient advocates, ...
(Date:8/4/2015)... FL (PRWEB) , ... August 04, 2015 , ... ... testing organization which provides vascular, electrocardiogram (EKG), echocardiogram, and NCV testing, announced their ... has been successfully identifying previously undiagnosed cardiovascular abnormalities one program at a time. ...
(Date:8/4/2015)... ... August 04, 2015 , ... Bayco Products, Inc. announces a new industrial-grade LED ... on hard hats that have a flip-up face shield. The sleek contours of the ... without having to remove their headlamp when raising or lowering their face shield or ...
(Date:8/4/2015)... ... August 04, 2015 , ... Worldwide ... Power Products is expanding its reach in Texas. Effective July 1st of this ... North Texas generator division. With the North Texas acquisition, Worldwide Power Products ...
Breaking Medicine News(10 mins):Health News:The Association between Chronic Pain and Obesity published by Dove Medical Press 2Health News:assistPoint.com Web Site Launched 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 3Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 2Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 3Health News:North Texas Acquisition Press Release 2
... News) -- Simple precautions will help keep you safe and ... for winter or put up holiday decorations, experts say. ... treated in U.S. emergency departments for holiday decorating-related falls, according ... of those injuries were caused by falls from ladders. ...
... find out whether a new drug or treatment makes ... life, according to a commentary published online December 3rd ... . Instead, most trials now are designed to detect ... which may not be clinically meaningful, write Alberto Ocana, ...
... -- New research explains why immune function actually improves in a ... cases, the virus has mutations that protect it against some HIV ... the researchers at the Mayo Clinic in Rochester, Minn. This ... equally bad for the immune system, the authors noted. "These ...
... leads to a decrease in adult stem cells and ... the offspring, according to new research from the University ... annual Society for Neuroscience meeting in San Diego in ... for behavioral problems such as attention-deficit hyperactivity disorder (ADHD) ...
... FRIDAY, Dec. 3 (HealthDay News) -- The impending extinction ... remove an important buffer against the transmission of infectious ... by the U.S. National Science Foundation and National Institutes ... the U.S. Environmental Protection Agency, focused on how the ...
... quarter of Americans live in rural areas, which consistently ... areas. Among the complex causes for this disparity is that ... almost 4 out of 10 rural residents live at ... the time, transportation, and financial resources for travel to urban ...
Cached Medicine News:Health News:Assessing positive outcomes of phase III trials 2Health News:Nicotine exposure in pregnant rats puts offspring at risk for learning disabilities 2Health News:Species Extinctions May Spell Trouble for Human Health 2Health News:ALBERT EINSTEIN COLLEGE OF MEDICINE HELPS ADDRESS NEED FOR IMPROVED CANCER CARE IN RURAL AMERICA 2
The Continuous Wave II Arthroscopy Pump provides pulse-free, continuous fluid inflow for joint distention when used in conjunction with a high flow sheath or separate inflow cannula....
... youre using, the Vortex Vacuum Mixer is clinically ... stirring up traditional vacuum mixers. The ergonomically angled ... The time-saving crank three revolutions every time ... and less stirring, cutting down on the amount ...
This high technology cast plaster cutter saw is very easy and comfortable to use....
De Soutter supply clean cast removal saws that are low in voltage and contain an integrated extractor system, combining state-of-the-art ergonomics with performance and durability....
Medicine Products: